Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1D1 | P20393 | 5/20 | 0.32 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.31 |
| ▸ | PLA2G10 | O15496 | 1/20 | 0.31 |
| ▸ | PLA2G5 | P39877 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3861378 | 0.87 | MGLL (0.32) | — | |
| SCHEMBL4815974 | 0.83 | MT-CO2 (0.33) | — | |
| SCHEMBL8740492 | 0.82 | STING1 (0.34) | PLA2G10PLA2G5 | |
| SCHEMBL4595993 | 0.82 | CTSD (0.32) | — | |
| SCHEMBL6433493 | 0.81 | — | — | |
| SCHEMBL2578067 | 0.81 | CA14 (0.33) | — | |
| SCHEMBL13747089 | 0.81 | MT-CO2 (0.34) | — | |
| SCHEMBL13012119 | 0.80 | OPRK1 (0.33) | — | |
| SCHEMBL16020547 | 0.80 | OPRK1 (0.36) | — | |
| SCHEMBL24276652 | 0.79 | DDB1 (0.34) | PLA2G10PLA2G5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130012432-A1 | Peptides for Treatment of Obesity | NOVO NORDISK A/S (DK) | 2013-01-10 | — | — | US | disclosed |
| US-20130012432-A1 | Peptides for Treatment of Obesity | NOVO NORDISK A/S (DK) | 2013-01-10 | — | — | US | disclosed |
| US-20130012432-A1 | Peptides for Treatment of Obesity | NOVO NORDISK A/S (DK) | 2013-01-10 | — | — | US | disclosed |
| EP-2539364-A1 | PEPTIDES FOR TREATMENT OF OBESITY | Novo Nordisk A/S (DK) | 2013-01-02 | — | — | EP | disclosed |
| US-20120021973-A1 | Peptides for Treatment of Obesity | NOVO NORDISK A/S (DK) | 2012-01-26 | — | — | US | disclosed |
| US-20120021973-A1 | Peptides for Treatment of Obesity | NOVO NORDISK A/S (DK) | 2012-01-26 | — | — | US | disclosed |
| US-20120021973-A1 | Peptides for Treatment of Obesity | NOVO NORDISK A/S (DK) | 2012-01-26 | — | — | US | disclosed |
| EP-2370104-A1 | PEPTIDES FOR TREATMENT OF OBESITY | Novo Nordisk A/S (DK) | 2011-10-05 | — | — | EP | disclosed |
| WO-2011104378-A1 | PEPTIDES FOR TREATMENT OF OBESITY | NOVO NORDISK A/S (DK) | 2011-09-01 | — | — | WO | disclosed |
| WO-2011104378-A1 | PEPTIDES FOR TREATMENT OF OBESITY | NOVO NORDISK A/S (DK) | 2011-09-01 | — | — | WO | disclosed |
| US-20100173835-A1 | Peptides for Treatment of Obesity | NOVO NORDISK A/S (DK) | 2010-07-08 | — | — | US | disclosed |
| US-20100173835-A1 | Peptides for Treatment of Obesity | NOVO NORDISK A/S (DK) | 2010-07-08 | — | — | US | disclosed |
| US-20100173835-A1 | Peptides for Treatment of Obesity | NOVO NORDISK A/S (DK) | 2010-07-08 | — | — | US | disclosed |
| WO-2010060901-A1 | PEPTIDES FOR TREATMENT OF OBESITY | NOVO NORDISK A/S (DK) | 2010-06-03 | — | — | WO | disclosed |
| WO-2010060901-A1 | PEPTIDES FOR TREATMENT OF OBESITY | NOVO NORDISK A/S (DK) | 2010-06-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120021973-A1 | Peptides for Treatment of Obesity | MC4R, GIPR, MC3R | NR1D1 806/4885NR1H3 654/4885PLA2G10 1958/4885 |
| US-20100173835-A1 | Peptides for Treatment of Obesity | MC4R, GIPR, MC3R | NR1D1 806/4885NR1H3 654/4885PLA2G10 1958/4885 |
| US-20130012432-A1 | Peptides for Treatment of Obesity | MC4R, GIPR, MC3R | NR1D1 806/4885NR1H3 654/4885PLA2G10 1958/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.